Imunon, Inc. (NASDAQ:IMNN) Receives $232.50 Average Price Target from Analysts

Shares of Imunon, Inc. (NASDAQ:IMNN) have earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $232.50.

Several brokerages have commented on IMNN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research note on Wednesday, October 8th. Brookline Capital Management reaffirmed a “buy” rating on shares of Imunon in a report on Wednesday.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. Riverview Capital Advisers LLC increased its stake in Imunon, Inc. (NASDAQ:IMNN) by 193.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,364 shares of the company’s stock after acquiring an additional 22,649 shares during the period. Riverview Capital Advisers LLC owned approximately 1.41% of Imunon worth $176,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Price Performance

IMNN stock opened at $3.69 on Wednesday. Imunon has a 1-year low of $2.99 and a 1-year high of $41.22. The business has a 50 day simple moving average of $3.87 and a two-hundred day simple moving average of $5.87. The company has a market capitalization of $11.33 million, a price-to-earnings ratio of -0.38 and a beta of 1.94.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.57. Sell-side analysts anticipate that Imunon will post -1.68 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.